(Q28199814)

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

tPA in acute ischemic stroke: United States experience and issues for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Ischemic penumbra: evidence from functional imaging in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Neuroimaging, the ischaemic penumbra, and selection of patients for acute stroke therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Comparison of admission perfusion computed tomography and qualitative diffusion- and perfusion-weighted magnetic resonance imaging in acute stroke patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Cerebral ischemia and reperfusion: the pathophysiologic concept as a basis for clinical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Pathophysiology of stroke: lessons from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Pathobiology of ischaemic stroke: an integrated view

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Mechanisms, challenges and opportunities in stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Trends in acute ischemic stroke trials through the 20th century

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Lubeluzole in acute ischemic stroke treatment: A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Clomethiazole acute stroke study (CLASS): results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Tolerability of NXY-059 at higher target concentrations in patients with acute stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Tolerability and pharmacokinetics of the nitrone NXY-059 in patients with acute stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

NXY-059 for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

A randomized efficacy trial of citicoline in patients with acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Cooling for Acute Ischemic Brain Damage (COOL AID): a feasibility trial of endovascular cooling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Vascular aspects of neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: neuroprotective effects when used alone or in combination with urokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Late secondary ischemic injury in patients receiving intraarterial thrombolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Do stroke units save lives?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571

Tissue plasminogen activator for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.12.1571